A simple change in kitchen seasoning cut the rate of strokes, major cardiovascular events, and deaths across 600 villages in rural northern China. The Salt Substitute and Stroke Study, a cluster-randomized trial registered as NCT02092090, assigned half of those villages to cook with a blend of 75 percent sodium chloride and 25 percent potassium chloride instead of regular table salt. The results, published in The New England Journal of Medicine, showed clear reductions in all three primary outcomes, and the World Health Organization has since issued a guideline recommending lower-sodium salt substitutes for people who season food at the table or during cooking.
Why a potassium-enriched salt blend matters for stroke prevention
High sodium intake raises blood pressure, and elevated blood pressure is the single largest modifiable risk factor for stroke. But reducing sodium is only half the story. Potassium acts through a separate pathway: it promotes renal sodium excretion and relaxes arterial walls. The SSaSS trial was designed to test whether a salt substitute containing 75 percent NaCl and 25 percent KCl could lower hard clinical endpoints, not just blood pressure readings on a chart.
An interim analysis of the trial documented measurable changes in urinary electrolytes and blood pressure before the final clinical results were tallied. Participants using the substitute excreted more potassium and less sodium, and their blood pressure dropped modestly compared with the control group. That pattern raises a testable question: were the stroke and mortality benefits driven more by the potassium increment than by the sodium decrement? Re-analyzing urinary electrolyte ratios against individual outcome risk within the existing trial data could separate those two contributions. If potassium turns out to be the stronger driver, it would shift public health strategy from “eat less salt” toward “eat better salt,” a distinction with real consequences for food labeling and product formulation.
Trial design and cardiovascular outcomes in SSaSS
SSaSS enrolled participants at high risk of stroke in rural north China, a population that relies heavily on discretionary salt for cooking and preserving food. The trial used cluster randomization at the village level, meaning entire communities received either the substitute blend or regular salt. That design reduced contamination between groups and reflected how salt is actually used in shared households and communal kitchens.
The primary results showed lower rates of stroke, major cardiovascular events, and all-cause death in the salt-substitute arm. Safety monitoring tracked hyperkalemia, the main clinical concern when adding potassium to the diet of older adults who may have impaired kidney function. The trial’s safety data did not show excess harm from hyperkalemia in the intervention group, a finding that carried significant weight when regulators and guideline panels assessed the evidence.
A Cochrane systematic review later synthesized randomized evidence on low-sodium salt substitutes, including SSaSS. That review confirmed SSaSS as the dominant source of clinical-outcome data in the field, with smaller trials contributing mainly blood-pressure evidence. The concentration of hard-endpoint evidence in a single large trial is both a strength and a limitation: the results are internally consistent and statistically powerful, but they come from one geographic and dietary context.
WHO guidance and the limits of scaling a kitchen swap
The World Health Organization responded to this evidence by issuing a guideline on lower-sodium salt substitutes. The WHO recommendation applies specifically to discretionary salt, the kind people add during cooking or at the table, and it includes cautions for populations with impaired potassium excretion, such as people with advanced kidney disease. The WHO evidence-to-recommendation framework weighed desirable versus undesirable effects, certainty of evidence, feasibility, equity, and acceptability before issuing the guidance.
Several questions remain open. Individual participant-level outcome data and exact event counts from the primary publication have not been released beyond aggregate results. Long-term hyperkalemia incidence and kidney-function trajectories after the trial ended are not yet reported in the registration record or the methods paper. And the village-level cost and supply-chain data needed to judge whether salt substitution can work outside rural China are absent from both the trial protocol and the WHO supporting documents.
Those gaps matter because the populations most likely to benefit, communities with high cardiovascular burden and heavy reliance on added salt, are often in low-income settings where potassium chloride costs more than regular salt and where routine kidney-function screening is unavailable. If a government or food manufacturer reformulates salt products without monitoring renal safety in vulnerable groups, the same swap that saved lives in northern China could cause harm elsewhere.
Another limitation is that SSaSS focused on discretionary salt, not the sodium hidden in processed foods, restaurant meals, or packaged snacks. In many urban and higher-income settings, most dietary sodium comes from industrially produced foods rather than the salt shaker. Even if every household cook adopted a potassium-enriched blend, the overall sodium load might fall only modestly unless food manufacturers also reformulated recipes at scale. That gap between kitchen-level change and food-system reality complicates efforts to generalize the trial’s impact to other countries.
Equity concerns also run through the implementation debate. Potassium-enriched products are often more expensive than standard table salt, especially in small packages sold in rural shops. Without subsidies or bulk purchasing programs, the households at greatest risk of stroke may be least able to afford the safer option. WHO’s framework recognizes these barriers but stops short of prescribing specific financing mechanisms, leaving national governments to decide whether to use taxes, vouchers, or public procurement to narrow the price gap.
Clinicians and public health officials must therefore walk a line between enthusiasm and caution. On one side is a compelling set of data linking a simple seasoning change to fewer strokes and deaths, backed by a large randomized trial and a global guideline. On the other is an incomplete picture of long-term kidney safety, real-world adherence, and economic feasibility in diverse food cultures. The prudent approach is to encourage potassium-enriched salt where it is affordable and acceptable, while pairing that advice with screening for kidney disease in older adults and those on medications that raise potassium.
The practical takeaway for readers who cook with added salt is straightforward: a potassium-enriched blend is the single dietary change with the strongest trial evidence for reducing stroke and death. People with kidney disease or those taking potassium-sparing medications should consult a physician before switching. For everyone else, the next thing to watch is whether national food regulators begin requiring or incentivizing potassium-enriched formulations in household salt, institutional kitchens, and eventually in processed foods. If policymakers can align safety monitoring, pricing, and supply chains with the science, the quiet act of changing what goes into a salt jar could become one of the most cost-effective cardiovascular interventions of this decade.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
